The pre-seed round was backed by Jenson Funding Partners to support platform development and service expansion.
"Without the ability to quickly and easily see a dermatologist, patients often go for months or even years without receiving proper treatment for acne, which can have a huge impact on emotional and mental health as well as the risk of causing permanent scarring. Typically, their treatment journey begins with online research, with resources varying in reliability, before trialling over-the-counter skin care products, which are not sufficient in a lot of cases."
The funding round was led by DSW Ventures to help expand manufacturing and commercial teams.
"This new partnership will enable us to build with confidence upon the foundation provided by Aston University and Innovate UK to commericalise iDPC at scale and to accelerate the development of innovative medicines."
The financing round was backed by ACF Investors, o2h Ventures, Jonathan Milner, and R42 Group.
"This latest funding will enable us to build on and accelerate our successful computational design-led discovery focus. We are excited to be playing a pivotal role in the innovation of oncological treatments leading to better outcomes for cancer patients worldwide. Our groundbreaking new approach stands to be initially validated by the proof-of-concept studies. We are achieving rapid progress not only with our industry-leading drug discovery programme, but also our proprietary AI platform. This has led to increasing interest from third parties in our machine learning capabilities, so we are keen to capitalise on this demand and establish a commercial effort in this area"
Foresight Williams Technology led the oversubscribed round alongside several regional and specialist investors.
"We are excited to announce our support for such a forward thinking and innovative business. Nebu~Flow’s development of delivery mechanisms tailored to specific drugs represents an opportunity to expand the market and improve patient outcomes. Foresight Williams Technology’s expertise will offer significant value as the Company develops its products, and we look forward to working with the team at Nebu~Flow during the next stage of their growth."
The Cheshire healthcare company has raised a financing facility from Tradeplus24 starting at £1.8m and scaling to £5m.
"We’re delighted to have received the funding approval from Tradeplus24. It’s a significant deal which underpins the wider confidence into the life sciences sector and one which will help us to bolster our presence across the UK."
